Bacon A, Makin J, Sizer P J, Jabbal-Gill I, Hinchcliffe M, Illum L, Chatfield S, Roberts M
Vaccine Research Unit (Medeva Group Development), Department of Biochemistry, Imperial College of Science and Technology, London SW7 2AY, United Kingdom.
Infect Immun. 2000 Oct;68(10):5764-70. doi: 10.1128/IAI.68.10.5764-5770.2000.
We have evaluated the ability of two carbohydrate biopolymers, chitosan and gellan, to enhance antibody responses to subunit influenza virus vaccines delivered to the respiratory tracts of mice. Groups of mice were vaccinated three times intranasally (i.n.) with 10 microg of purified influenza B/Panama virus surface antigens (PSAs), which consist of hemagglutinin (HA) and neuraminidase (NA), either alone or admixed with chitosan or gellan solutions. Separate groups were vaccinated subcutaneously (s.c.) with PSAs adsorbed to Alhydrogel or chitosan or gellan alone i.n. Serum antibody responses were determined by enzyme-linked immunosorbent assay (ELISA) for influenza virus-specific immunoglobulin G (IgG) and by HA inhibition (HAI) and NA inhibition (NAI) assays. The local respiratory immune response was measured by assaying for influenza virus-specific IgA antibody in nasal secretions and by enumerating nasal and pulmonary lymphocytes secreting IgA, IgG, and IgM anti-influenza virus-specific antibodies by enzyme-linked immunospotting (ELISPOT). When administered alone i.n., B/Panama PSA was poorly immunogenic. Parenteral immunization with B/Panama PSA with Alhydrogel elicited high titers of anti-B/Panama antibodies in serum but a very poor respiratory anti-B/Panama IgA response. In contrast, i.n. immunization with PSA plus chitosan stimulated very strong local and systemic anti-B/Panama responses. Gellan also enhanced the local and serum antibody responses to i.n. PSA but not to the same extent as chitosan. The ability of chitosan to augment the immunogenicity of influenza vaccines given i.n. was confirmed using PSA prepared from an influenza A virus (A/Texas H1N1).
我们评估了两种碳水化合物生物聚合物壳聚糖和结冷胶增强小鼠呼吸道接种亚单位流感病毒疫苗抗体反应的能力。将小鼠分组,每组经鼻内(i.n.)接种3次,每次接种10微克纯化的乙型/巴拿马流感病毒表面抗原(PSA),该抗原由血凝素(HA)和神经氨酸酶(NA)组成,单独接种或与壳聚糖或结冷胶溶液混合接种。另一组单独经鼻内接种吸附于氢氧化铝凝胶的PSA或壳聚糖或结冷胶,还有一组经皮下(s.c.)接种吸附于氢氧化铝凝胶的PSA。通过酶联免疫吸附测定(ELISA)检测流感病毒特异性免疫球蛋白G(IgG)的血清抗体反应,并通过血凝抑制(HAI)和神经氨酸酶抑制(NAI)试验进行检测。通过检测鼻分泌物中流感病毒特异性IgA抗体,并通过酶联免疫斑点法(ELISPOT)计数分泌抗流感病毒特异性IgA、IgG和IgM抗体的鼻和肺淋巴细胞,来测量局部呼吸道免疫反应。单独经鼻内接种时,乙型/巴拿马PSA免疫原性较差。用吸附于氢氧化铝凝胶的乙型/巴拿马PSA进行胃肠外免疫接种可在血清中引发高滴度的抗乙型/巴拿马抗体,但呼吸道抗乙型/巴拿马IgA反应非常弱。相比之下,用PSA加壳聚糖经鼻内免疫接种可刺激非常强烈的局部和全身抗乙型/巴拿马反应。结冷胶也增强了经鼻内接种PSA后的局部和血清抗体反应,但程度不如壳聚糖。使用甲型流感病毒(A/德克萨斯H1N1)制备的PSA证实了壳聚糖增强经鼻内接种流感疫苗免疫原性的能力。